BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19030751)

  • 1. Impact of extended lymphadenectomy on morbidity, mortality, recurrence and 5-year survival after gastrectomy for cancer. Meta-analysis of randomized clinical trials.
    Lustosa SA; Saconato H; Atallah AN; Lopes Filho Gde J; Matos D
    Acta Cir Bras; 2008; 23(6):520-30. PubMed ID: 19030751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extent of lymph node dissection for adenocarcinoma of the stomach.
    Mocellin S; McCulloch P; Kazi H; Gama-Rodrigues JJ; Yuan Y; Nitti D
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD001964. PubMed ID: 26267122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of D1 versus D2 gastrectomy for gastric adenocarcinoma.
    Memon MA; Subramanya MS; Khan S; Hossain MB; Osland E; Memon B
    Ann Surg; 2011 May; 253(5):900-11. PubMed ID: 21394009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic benefit of extended radical lymphadenectomy for patients with gastric cancer.
    Ikeguchi M; Oka S; Gomyo Y; Tsujitani S; Maeta M; Kaibara N
    Anticancer Res; 2000; 20(2B):1285-9. PubMed ID: 10810436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WITHDRAWN: Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach.
    McCulloch P; Nita ME; Kazi H; Gama-Rodrigues JJ
    Cochrane Database Syst Rev; 2012 Jan; 1():CD001964. PubMed ID: 22258947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach.
    McCulloch P; Nita ME; Kazi H; Gama-Rodrigues J
    Cochrane Database Syst Rev; 2004 Oct; (4):CD001964. PubMed ID: 15495024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach.
    McCulloch P; Nita ME; Kazi H; Gama-Rodrigues J
    Cochrane Database Syst Rev; 2003; (4):CD001964. PubMed ID: 14583942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective randomized controlled trial to compare laparoscopic distal gastrectomy (D2 lymphadenectomy plus complete mesogastrium excision, D2 + CME) with conventional D2 lymphadenectomy for locally advanced gastric adenocarcinoma: study protocol for a randomized controlled trial.
    Shen J; Cao B; Wang Y; Xiao A; Qin J; Wu J; Yan Q; Hu Y; Yang C; Cao Z; Hu J; Yin P; Xie D; Gong J
    Trials; 2018 Aug; 19(1):432. PubMed ID: 30092843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer.
    McCulloch P; Niita ME; Kazi H; Gama-Rodrigues JJ
    Br J Surg; 2005 Jan; 92(1):5-13. PubMed ID: 15635680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Total gastrectomy for gastric cancer: can the type of lymphadenectomy condition the long-term results?].
    Di Martino N; Izzo G; Cosenza A; Vicenzo L; Monaco L; Torelli F; Basciotti A; Brillantino A; Marra A
    Suppl Tumori; 2005; 4(3):S84-5. PubMed ID: 16437920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Patients with Localized and Resectable Gastric Cancer, What is the Optimal Extent of Lymph Node Dissection-D1 Versus D2 Versus D3?
    Mogal H; Fields R; Maithel SK; Votanopoulos K
    Ann Surg Oncol; 2019 Sep; 26(9):2912-2932. PubMed ID: 31076930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphadenectomy extent and survival of patients with gastric carcinoma: a systematic review and meta-analysis of time-to-event data from randomized trials.
    Mocellin S; Nitti D
    Cancer Treat Rev; 2015 May; 41(5):448-54. PubMed ID: 25814393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer.
    Degiuli M; Sasako M; Ponti A; Vendrame A; Tomatis M; Mazza C; Borasi A; Capussotti L; Fronda G; Morino M;
    Br J Surg; 2014 Jan; 101(2):23-31. PubMed ID: 24375296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Distal subtotal gastrectomy and gastreectomy in surgical treatment of patients with gastric cancer: a systematic review and meta-analysis].
    Panin SI; Postolov MP; Kovalenko NV; Beburishvili AG; Fedorov AV; Bykov AV
    Khirurgiia (Mosk); 2020; (11):93-100. PubMed ID: 33210514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resection for gastric cancer in the community.
    van de Velde CJ
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S90-3. PubMed ID: 16399441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is D2 lymphadenectomy in gastrectomy safe with regard to the skill of the operator?
    Moriwaki Y; Kobayashi S; Kunisaki C; Harada H; Imai S; Kido Y; Kasaoka C
    Dig Surg; 2001; 18(2):111-7. PubMed ID: 11351155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does D3 surgery offer a better survival outcome compared to D1 surgery for gastric cancer? A result based on a hospital population of two decades as taking D2 surgery for reference.
    Zhang H; Liu C; Wu D; Meng Y; Song R; Lu P; Wang S
    BMC Cancer; 2010 Jun; 10():308. PubMed ID: 20565910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laparoscopic vs open D2 gastrectomy for locally advanced gastric cancer: a meta-analysis.
    Zou ZH; Zhao LY; Mou TY; Hu YF; Yu J; Liu H; Chen H; Wu JM; An SL; Li GX
    World J Gastroenterol; 2014 Nov; 20(44):16750-64. PubMed ID: 25469048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome after D1 vs D2-3 gastrectomy for treatment of gastric cancer.
    Danielson H; Kokkola A; Kiviluoto T; Sirén J; Louhimo J; Kivilaakso E; Puolakkainen P
    Scand J Surg; 2007; 96(1):35-40. PubMed ID: 17461310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: a meta-analysis.
    Jiang L; Yang KH; Guan QL; Zhao P; Chen Y; Tian JH
    J Surg Oncol; 2013 Jun; 107(8):807-14. PubMed ID: 23512524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.